Kalaris Therapeutics Stock Forecast
NASDAQ: KLRSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 2.36 0.00%
KLRS analyst consensus
Consensus (8 analysts)
strong_buy
Avg. price target
$18.71+692.80%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering Kalaris Therapeutics (2026-10-09), 7 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $18.71, with a high estimate of $25.00 and a low estimate of $7.00. The average target implies upside of 692.8% from the current price of $2.36.
The spread between the highest and lowest targets is 257.1%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for KLRS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 25% |
| Buy | 5 | 63% |
| Hold | 1 | 13% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $7.00 | +196.61% |
| Average target | $18.71 | +692.80% |
| High target | $25.00 | +959.32% |